Covance Launches New Brand: Solutions Made Real™
PRINCETON, N.J., May 1, 2014 /PRNewswire/ -- Covance Inc. (NYSE: CVD), the world's most comprehensive drug development company, today announced its new brand, Solutions Made RealTM. This brand strategy more effectively articulates Covance's evolution as a partner capable of transforming today's challenges into tomorrow's healthcare advances by delivering lifesaving drugs faster and more efficiently. In addition, Solutions Made Real reflects the depth and breadth of the company's industry experience as well as its unique insights on leading-edge trends in drug development and nutritional analysis.
"Covance is known for providing outstanding operational, scientific and service excellence for our clients. With the healthcare, biopharmaceutical and food industries continuing to evolve, our clients now expect more proactive, insightful and resourceful solutions," said Joe Herring, Covance Chairman and Chief Executive Officer. "The old paradigm of using outsourcing as simply auxiliary arms and legs has given way to a more comprehensive, thoughtful approach.
"Our clients need better solutions to address the complex challenges they face and are looking to enhance their partnership with companies that are resourceful and insightful."
Covance produces more safety and efficacy data to support drug approvals than any other company worldwide. This critical information provides a unique perspective on drug development trends. Covance's ability to effectively apply proprietary methods of analytics across data generated in thousands of trials and tests delivers a significant advantage for our clients by accelerating their drug development projects.
Covance has also made additional investments in informatics and data visualization expertise to help drive a set of transformational service offerings. The company's proprietary knowledgebase, Xcellerate®, has already saved tens of millions of dollars in individual clinical trial costs and significantly accelerated the timelines of numerous clinical programs, allowing clients to get to market sooner with longer patent protection and improved NPVs.
"Our people bring valuable perspectives and are proactively helping clients identify new approaches and anticipate tomorrow's challenges," added Mr. Herring. "Together with our clients, Covance transforms today's healthcare challenges into tomorrow's Solutions Made Real."
Covance, the world's most comprehensive drug development company and a leader in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made Real TM. The company, headquartered in Princeton, New Jersey, has annual revenues greater than $2.4 billion and more than 12,000 employees located in over 60 countries. Information on Covance's solutions, recent press releases, and SEC filings can be obtained through its website at www.covance.com
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
SOURCE Covance Inc.